Pharma Merger

Directors are selling CoLucid Pharmaceuticals too cheaply through an unfair process to Eli Lilly, for $46.50 a share or $897 million, shareholders say in a federal class action.

BOSTON – Directors are selling CoLucid Pharmaceuticals too cheaply through an unfair process to Eli Lilly, for $46.50 a share or $897 million, shareholders say in a federal class action.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Pharma Merger

Subscribe to Closing Arguments

Additional Reads